Generics Bulletin Editor’s Picks For Q2 2023
Highlights Across The Off-Patent Sector From April To June 2023
Executive Summary
Looking back over the second quarter of 2023, Generics Bulletin executive editor Dave Wallace picks out highlights from April to June that include strategic updates from some of the off-patent industry’s biggest players, several exclusive interviews, and the build-up to the second wave of biosimilar competition to Humira in the US.